Clinical trials: Subcutaneous Injections
Migraine
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
The purpose of this study is: To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet…
- Trial name
- NCT01507610
- Testing
- Sumatriptan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Optinose US Inc.
Characteristics of Subcutaneous Fat
ATX-101 Abdominoplasty
Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty
- Trial name
- ATX-101-08-10 (NCT00835952)
- Testing
- ATX-101
- Where
- 2 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Moderate to Severe Plaque Psoriasis
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of SHR-1139 injection in healthy subjects who receive a single subcutaneous injection or intravenous infusion of…
- Trial name
- NCT07051538
- Testing
- SHR-1139 Injections
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Hypercholesterolemia
Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
Primary Objective: Injection Site Tolerability Secondary Objectives: To assess the safety profile of alirocumab SAR236553 (REGN727) To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
- Trial name
- NCT01448239
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pharmacodynamics, Pharmacokinetics
Double-blind, Randomized Comparative Cross-sectional Study of Pharmacodynamics and Pharmacokinetics of Drugs GP40141
Bioequivalence Study of GP40141 (GEROPHARM) versus Enplate®. The study of comparative pharmacodynamics, pharmacokinetics and safety of drugs containing romiplostim in healthy volunteers after a single subcutaneous injection.
- Conditions
- Pharmacodynamics, Pharmacokinetics, Bioequivalence
- Trial name
- NCT05652595
- Testing
- GP40141, Nplate
- Where
- Russia
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Geropharm
Chronic Weight Management
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.
- Trial name
- NCT06972992
- Testing
- ASC47 +Semaglutide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Healthy
Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®
To compare the pharmacokinetic characteristic of LBEC0101 25mg with active comparator, Enbrel® 25mg.
- Trial name
- NCT01725620
- Testing
- LBEC0101 (Etanercept 25mg), Enbrel (Etanercept 25mg)
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
IgA Nephropathy
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
The study is being conducted to Evaluate the Safety, Tolerability and Pharmacokinetics pharmacodynamics of SHR-2010 by intravenously/subcutaneously in Healthy Subject.
- Trial name
- NCT05398510
- Testing
- SHR-2010 injection
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy Volunteers, Obesity
Phase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity
This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MWN117 injection in healthy and…
- Trial name
- NCT07824804
- Testing
- MWN117
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Safety, Pharmacokinetics
A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects
This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects
- Conditions
- Safety, Pharmacokinetics, Healthy Subjects
- Trial name
- NCT02601625
- Testing
- Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to…
- Trial name
- NCT07489599
- Testing
- QLH2405
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy
Comparative Clinical Study of Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers
This clinical study is a phase 1 study which carried out to establish the pharmacokinetic equivalence and equal safety and tolerability profile of BCD-057 (adalimumab biosimilar candidate manufactured by CJSC BIOCAD, Russia) and…
- Trial name
- NCT02395055
- Testing
- Adalimumab (BCD-057), Adalimumab (Humira)
- Where
- Russia
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Biocad
Hyperlipemia
Safety and Tolerability of SHR-1918 in Healthy Subjects
The primary objective of this study is to assess the safety and tolerability of SHR-1918 injection in healthy subjects. In addition, this study will provide information on pharmacokinetics and pharmacodynamics of SHR-1918…
- Trial name
- NCT05432544
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Injection Site Irritation, Injection Site Bruising
Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline
This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject.
- Conditions
- Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction
- Trial name
- NCT05109000
- Testing
- Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jeffrey Alan Klein, MD
Pharmacokinetics of ASP2408, Healthy Subjects
A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) after intravenous (IV) administration of ASP2408 manufactured from a new production clone and also following single ascending doses of…
- Trial name
- NCT02150070
- Testing
- ASP2408
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Systemic Lupus Erythematosus
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
A Double-blind, Randomized, Placebo-controlled, Dose-escalation Phase I Study to Assess the Safety and PK/PD of LBL-047 Subcutaneous Injection in Healthy Adults and Patients with Systemic Lupus Erythematosus.
- Trial name
- NCT07323173
- Testing
- LBL-047 for Injection
- Where
- 12 sites in China
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Healthy Volunteer
Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose
This is a phase 1b, open-label, single dose study in healthy male subjects. Approximately 12 healthy male subjects will receive a subcutaneous injection of denosumab on Day 1.
- Trial name
- NCT01869686
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Subjects
Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Subjects After Subcutaneous Injection of TISA-818-Inj
This is a single-centre, randomised, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability, and pharmacokinetic (PK) profile, of TISA-818-Inj-5mg/mL after single and multiple s.c.
- Trial name
- TISA-818-Inj (NCT07337044)
- Testing
- TISA-818-Inj
- Where
- Sweden
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
HIV
A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults
Background: HIV is a serious disease with no cure or vaccine to prevent it. Using antibodies could be a way to prevent HIV infection. Antibodies are made by the human body to fight germs.
- Trial name
- VRC 611 (NCT04408963)
- Testing
- VRC-HIVMAB0102-00-AB
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
The purpose of this research is to evaluate the safety and pharmacokinetic profile of single doses of ATX-101
- Trial name
- NCT00618709
- Testing
- ATX-101
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals